• M Janelle Cambron-Mellott, Jaromir Mikl, Joana E Matos, Jennifer G Erensen, Kathleen Beusterien, Marc J Cataldo, Bernadette Hallissey, and Gregory W Mattingly.
• Kantar Health, New York, NY, USA.
• Patient Prefer Adher. 2021 Jan 1; 15: 106110731061-1073.

Background And ObjectiveTreatment for attention deficit hyperactivity disorder (ADHD) requires a multifaceted approach including psychosocial interventions and pharmacological treatment. This study evaluates preferences for specific attributes associated with different long-acting stimulant treatment among US adults with ADHD.MethodsPatients completed an online, cross-sectional survey, incorporating a discrete choice experiment to assess preferences for attributes.ResultsAnalyses included 200 adults with ADHD (mean age 33.0 years; 60% self-reporting moderate severity); the mean (SD) Adult ADHD Self-Report Scale-v1.1 score was 45.9 (12.4). Overall, patients valued speed of onset most and risk of rebound least. Three population groups with distinct preferences were identified: side effect-driven (n=69, 35%), quick onset-driven (n=47, 24%) and quick onset and long duration-driven (n=84, 42%).ConclusionThis study shows differences in how adults with ADHD value and assess benefit-risk trade-offs when considering the desired attributes of stimulant treatments, highlighting the importance of patient-physician shared decision-making to optimize the desired benefits of individualized treatment.© 2021 Cambron-Mellott et al.

5 keywords...

hide…